🔴 Biovie is trading 13.17% down in pre-market

Biovie is trading at $1.25 with a -13.17% change in pre-market; available search results identified no confirmed company-specific catalyst for the October 28 decline.

• Coverage of BioVie’s Long COVID trial reported no statistically significant results across all participants, alongside some positive subgroup findings; it did not link the coverage to this move.
• The prior-day NIH workshop announcement is recent company news, but available information does not establish it as the reason for the decline.